Press release from Companies

Publicerat: 2019-05-03 08:30:00

Scandion Oncology: Scandion Oncology A/S Annual Report 2018 published

Scandion Oncology A/S hereby publishes the Annual Report for 2018. The Annual Report 2018 is available on the company"s website (www.scandiononcology.com).

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com 


Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology was listed on Spotlight, Sweden in November 2018.

Läs mer hos Cision
Läs mer om Scandion Oncology